Clinical trials: Hepatocellular Carcinoma With PVTT
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus toripalimab versus hepatic arterial infusion chemotherapy of…
- Trial name
- NCT04135690
- Testing
- Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection
- Trial name
- NCT02813096
- Testing
- folfox4 chemotherapy regimen
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Patients with hepatocellular carcinoma with PVTT can benefit from surgical resection and radiotherapy. As the rapid development of systematic treatment in hepatocellular carcinoma, ICIs neoadjuvant therapy is being actively…
- Trial name
- NCT05225116
- Testing
- Sintilimab, Lenvatinib, radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT
To explore the efficacy and safety of toripalimab plus stereotactic body radiotherapy for hepatocellular carcinom with portal vein tumor thrombus.
- Trial name
- NCT04169399
- Testing
- Toripalimab, Stereotactic body radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Radiotherapy, Toripalimab
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
To explore the efficacy of radiotherapy plus toripalimab Versus standard treatment of sorafenib in advanced hepatocellular carcinoma with Portal Vein/Hepatic vein Tumor Thrombosis.
- Conditions
- Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma
- Trial name
- NCT04709380
- Testing
- Radiotherapy plus Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma Non-resectable
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and iodion-125 seeds brachytherapy (TACE-Len-I) compared with TACE combined with lenvatinib (TACE-Len)…
- Trial name
- NCT04967495
- Testing
- TACE combined with lenvatinib and iodion-125 seeds brachytherapy, TACE combined with lenvatinib
- Where
- China
- Volunteers
- 171 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C.
- Trial name
- NCT06248528
- Testing
- Liver resection, Locoregional therapy
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Chen Xiaoping
Hepatocellular Carcinoma
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.
- Trial name
- CORTT (NCT02301091)
- Testing
- TACE, RFA, pirarubicin,mitomycin and lobaplatin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Ming Zhao
Liver Cancer, Liver Transplant; Complications
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
This is a parallel assigned, open-label, perspective trial studying the safety and efficacy of intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for Hepatocellular Carcinoma (HCC) with Vp3 Portal…
- Conditions
- Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- iPLENTY-pvtt (NCT05339581)
- Testing
- intensity-modulated radiotherapy, Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- RenJi Hospital
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT
This is a multicentri prospective cohort study to investigate the safety and efficacy of external beam radiation (RT) combined with transarterial chemoembolization (TACE) and lenvatinib vs TACE and lenvatinib in the treatment of…
- Trial name
- NCT05592197
- Testing
- Lenvatinib, TACE, External beam radiation (RT)
- Where
- China
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
- Trial name
- NCT04387695
- Testing
- SBRT+TACE+Sorafenib, Sorafenib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hepatocellular Carcinoma
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Hepatocellular carcinoma (HCC) is characterized with vascular invasion, particularly of the portal vein, resulting in portal vein tumor thrombus (PVTT) in 10%-40% of HCC patients at the time of HCC diagnosis.
- Trial name
- NCT05535998
- Testing
- TACE-HAIC, TACE, Targeted therapy
- Where
- China
- Volunteers
- 743 people
- Sponsor
- Yunfei Yuan
Stage IIIA Hepatocellular Carcinoma
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).
- Trial name
- NCT06061445
- Testing
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma Non-resectable
Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of…
- Trial name
- NCT05530785
- Testing
- radiotherapy combined with sintilimab and bevacizumab biosimilar
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Yongchang Zhang